NASDAQ:SCYX - SCYNEXIS News Headlines

Sign in or create an account to add this stock to your watchlist.
$0.89 +0.05 (+5.95 %)
(As of 11/14/2018 04:00 PM ET)
Previous Close$0.84
Today's Range$0.86 - $0.90
52-Week Range$0.82 - $2.45
Volume2,016 shs
Average Volume386,762 shs
Market Capitalization$41.61 million
P/E Ratio-0.86
Dividend YieldN/A
Beta0.59

Headlines

SCYNEXIS (NASDAQ SCYX) News Headlines

Source:
DateHeadline
SCYNEXIS (SCYX) Releases Quarterly  Earnings ResultsSCYNEXIS (SCYX) Releases Quarterly Earnings Results
www.americanbankingnews.com - November 14 at 12:16 PM
SCYNEXIS, Inc.SCYNEXIS, Inc.
www.streetinsider.com - November 14 at 8:13 AM
SCYNEXIS beats by $0.15, misses on revenueSCYNEXIS beats by $0.15, misses on revenue
seekingalpha.com - November 13 at 5:14 PM
Scynexis: 3Q Earnings SnapshotScynexis: 3Q Earnings Snapshot
finance.yahoo.com - November 13 at 5:14 PM
SCYNEXIS Reports Third Quarter 2018 Financial Results and Provides Company UpdateSCYNEXIS Reports Third Quarter 2018 Financial Results and Provides Company Update
finance.yahoo.com - November 13 at 5:14 PM
Scynexis (SCYX) Reports Q3 Loss, Tops Revenue EstimatesScynexis (SCYX) Reports Q3 Loss, Tops Revenue Estimates
finance.yahoo.com - November 13 at 5:14 PM
SCYNEXIS (SCYX) Given a $4.00 Price Target at Maxim GroupSCYNEXIS (SCYX) Given a $4.00 Price Target at Maxim Group
www.americanbankingnews.com - November 13 at 1:27 PM
Will Scynexis (SCYX) Report Negative Earnings Next Week? What You Should KnowWill Scynexis (SCYX) Report Negative Earnings Next Week? What You Should Know
www.zacks.com - October 31 at 8:15 AM
SCYNEXIS Inc (SCYX) Receives Consensus Recommendation of "Buy" from AnalystsSCYNEXIS Inc (SCYX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - October 27 at 2:40 AM
SCYNEXIS Announces FDA Agreement with Company-Proposed Phase 3 Vulvovaginal Candidiasis Program for Oral IbrexafungerpSCYNEXIS Announces FDA Agreement with Company-Proposed Phase 3 Vulvovaginal Candidiasis Program for Oral Ibrexafungerp
finance.yahoo.com - October 23 at 5:08 PM
HC Wainwright Analysts Give SCYNEXIS (SCYX) a $5.00 Price TargetHC Wainwright Analysts Give SCYNEXIS (SCYX) a $5.00 Price Target
www.americanbankingnews.com - October 23 at 2:56 PM
SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida ...SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida ...
www.prnewswire.com - October 17 at 5:01 PM
SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida auris Infections (CARES)SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida auris Infections (CARES)
finance.yahoo.com - October 15 at 5:09 PM
SCYNEXIS Supports AMR Challenge and Fungal Disease Awareness WeekSCYNEXIS Supports AMR Challenge and Fungal Disease Awareness Week
finance.yahoo.com - October 1 at 4:59 PM
SCYNEXIS to Present an Overview of the Companys Pipeline at IDWeek 2018SCYNEXIS to Present an Overview of the Company's Pipeline at IDWeek 2018
finance.yahoo.com - September 26 at 8:20 AM
SCYNEXIS, Inc. to Present at Upcoming Investor ConferencesSCYNEXIS, Inc. to Present at Upcoming Investor Conferences
finance.yahoo.com - September 25 at 8:12 AM
Who Owns SCYNEXIS Inc (NASDAQ:SCYX)?Who Owns SCYNEXIS Inc (NASDAQ:SCYX)?
finance.yahoo.com - September 18 at 5:01 PM
SCYNEXIS, Inc. to Participate in Upcoming Investor ConferencesSCYNEXIS, Inc. to Participate in Upcoming Investor Conferences
finance.yahoo.com - August 29 at 8:23 AM
SCYNEXIS misses by $0.06, misses on revenueSCYNEXIS misses by $0.06, misses on revenue
seekingalpha.com - August 10 at 8:15 AM
Scynexis (SCYX) Reports Q2 Loss, Lags Revenue EstimatesScynexis (SCYX) Reports Q2 Loss, Lags Revenue Estimates
finance.yahoo.com - August 10 at 8:15 AM
Scynexis: 2Q Earnings SnapshotScynexis: 2Q Earnings Snapshot
finance.yahoo.com - August 9 at 6:08 PM
SCYNEXIS Reports Second Quarter 2018 Financial Results and Provides Company UpdateSCYNEXIS Reports Second Quarter 2018 Financial Results and Provides Company Update
finance.yahoo.com - August 9 at 6:08 PM
The World Health Organization Recognizes New Antifungal Class by Granting "ibrexafungerp" to SCYNEXIS as the International Non-Proprietary Name for SCY-078The World Health Organization Recognizes New Antifungal Class by Granting "ibrexafungerp" to SCYNEXIS as the International Non-Proprietary Name for SCY-078
finance.yahoo.com - July 18 at 4:53 PM
Week Ahead In Pharmaceuticals - 7 Stocks To WatchWeek Ahead In Pharmaceuticals - 7 Stocks To Watch
www.nasdaq.com - July 14 at 3:39 PM
SCYNEXIS: An Update On This ~$2 Lottery TicketSCYNEXIS: An Update On This ~$2 'Lottery Ticket'
seekingalpha.com - July 14 at 3:39 PM
Why Scynexis Stock Rose 16.4% YesterdayWhy Scynexis Stock Rose 16.4% Yesterday
finance.yahoo.com - July 12 at 4:49 PM
Biotech Analysis Central Pharma News: Pfizers Unit Separation, BioCrysts Merger Collapses, Scynexis Positive Mid-Stage ResultsBiotech Analysis Central Pharma News: Pfizer's Unit Separation, BioCryst's Merger Collapses, Scynexis' Positive Mid-Stage Results
seekingalpha.com - July 12 at 8:15 AM
SCYNEXIS selects dose regimen for late-stage studies of antifungal SCY-078SCYNEXIS selects dose regimen for late-stage studies of antifungal SCY-078
seekingalpha.com - July 11 at 8:12 AM
Scynexis (SCYX) Reports Positive Results from Phase 2b Dose-Finding Study of Oral SCY-078 in VVCScynexis (SCYX) Reports Positive Results from Phase 2b Dose-Finding Study of Oral SCY-078 in VVC
www.streetinsider.com - July 10 at 5:00 PM
SCYNEXIS Reports Positive Results from Phase 2b Dose-Finding Study of Oral SCY-078 in Vulvovaginal CandidiasisSCYNEXIS Reports Positive Results from Phase 2b Dose-Finding Study of Oral SCY-078 in Vulvovaginal Candidiasis
finance.yahoo.com - July 10 at 5:00 PM
Complimentary Technical Snapshots on Mylan and Three More Generic Drugs StocksComplimentary Technical Snapshots on Mylan and Three More Generic Drugs Stocks
finance.yahoo.com - July 2 at 8:23 AM
SCYNEXIS Announces the Presentation of SCY-078 Data at the Teratology Society 58th Annual MeetingSCYNEXIS Announces the Presentation of SCY-078 Data at the Teratology Society 58th Annual Meeting
finance.yahoo.com - June 27 at 8:48 AM
Scynexis, Undervalued And Filling A Critical Need In The Antifungal SpaceScynexis, Undervalued And Filling A Critical Need In The Antifungal Space
seekingalpha.com - June 26 at 5:20 PM
Form 8-K SCYNEXIS INC For: Jun 14Form 8-K SCYNEXIS INC For: Jun 14
www.streetinsider.com - June 22 at 5:45 PM
SCYNEXIS to Present SCY-078 Data at Three Scientific Meetings in June/July 2018SCYNEXIS to Present SCY-078 Data at Three Scientific Meetings in June/July 2018
finance.yahoo.com - June 14 at 8:18 AM
SCYNEXIS Presents SCY-078 Data at ASM Microbe 2018SCYNEXIS Presents SCY-078 Data at ASM Microbe 2018
finance.yahoo.com - June 11 at 5:14 PM
Your Daily Pharma Scoop: Scynexis Moves Up, Proteostasis Disappoints Investors, Cellectar ZoomsYour Daily Pharma Scoop: Scynexis Moves Up, Proteostasis Disappoints Investors, Cellectar Zooms
seekingalpha.com - June 11 at 8:12 AM
SCYNEXIS announces publication of early-stage SCY-078 data; shares up 2% premarketSCYNEXIS announces publication of early-stage SCY-078 data; shares up 2% premarket
seekingalpha.com - June 6 at 5:31 PM
SCYNEXIS to Present SCY-078 Data at ASM Microbe 2018SCYNEXIS to Present SCY-078 Data at ASM Microbe 2018
finance.yahoo.com - May 24 at 5:46 PM
Free Daily Technical Summary Reports on Mylan and Three Other Generic Drugs StocksFree Daily Technical Summary Reports on Mylan and Three Other Generic Drugs Stocks
finance.yahoo.com - May 24 at 8:15 AM
SCYNEXIS to Participate in a Panel at the 2018 BIO International ConventionSCYNEXIS to Participate in a Panel at the 2018 BIO International Convention
finance.yahoo.com - May 23 at 5:40 PM
What’s Behind the 28% Hike in SCYNEXIS Stock Last Week?What’s Behind the 28% Hike in SCYNEXIS Stock Last Week?
finance.yahoo.com - May 22 at 8:16 AM
SCYNEXIS beats by $0.08, misses on revenueSCYNEXIS beats by $0.08, misses on revenue
seekingalpha.com - May 9 at 8:15 AM
Scynexis: 1Q Earnings SnapshotScynexis: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 8:14 AM
SCYNEXIS Reports First Quarter 2018 Financial Results and Provides Company UpdateSCYNEXIS Reports First Quarter 2018 Financial Results and Provides Company Update
finance.yahoo.com - May 8 at 5:45 PM
Roth Capital Assumes SCYNEXIS (SCYX) at BuyRoth Capital Assumes SCYNEXIS (SCYX) at Buy
www.streetinsider.com - May 8 at 8:12 AM
Benzingas Top Upgrades, Downgrades For May 7, 2018Benzinga's Top Upgrades, Downgrades For May 7, 2018
www.benzinga.com - May 7 at 5:43 PM
UPDATE: HC Wainwright Starts SCYNEXIS (SCYX) at BuyUPDATE: HC Wainwright Starts SCYNEXIS (SCYX) at Buy
www.streetinsider.com - May 7 at 8:15 AM
Scynexis (SCYX) Granted FDA Fast Track & Qualified Infectious Disease Product Designation for Oral SCY-078Scynexis (SCYX) Granted FDA Fast Track & Qualified Infectious Disease Product Designation for Oral SCY-078
www.streetinsider.com - May 2 at 8:17 AM
SCYNEXISs Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention ...SCYNEXIS's Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention ...
www.prnewswire.com - May 1 at 5:21 PM
This page was last updated on 11/14/2018 by MarketBeat.com Staff

Featured Article: 52-Week High/Low

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel